VisiPlate® Aqueous Shunt Safety and Effectiveness data from VITA Clinical Trial to be presented at the 2024 South Africa Glaucoma Society Annual Congress

Illustration of a doctor examining a patient's eye for glaucoma, representing the work of the South African Glaucoma Society and advancements in glaucoma treatment.

Interim trial results demonstrate the safety and effectiveness of VisiPlate® as a standalone treatment for primary open-angle glaucoma.


REDWOOD CITY, Calif., (May 14, 2024) – Avisi Technologies, Inc., an ophthalmic-focused medical device manufacturer, is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. Avisi’s flagship product, VisiPlate, is a nanotechnology-enabled implant to treat glaucoma. Today, Avisi announced that data from its second clinical trial of its proprietary glaucoma technology, the VisiPlate Aqueous Shunt, will be presented in an oral presentation at this year’s South Africa Glaucoma Society (SAGS) Congress meeting May 24th to 26th at the Capital Zimbali Resort, in KwaZulu-Natal. The data from the VITA trial will be presented by study Principle Investigator Lynette Venter, MBChB, MMed (Ophth) FC, Ophth (SA).

VisiPlate is a nanotechnology-enabled aqueous shunt designed to lower eye pressure in glaucoma patients. Many times thinner than a single hair, VisiPlate lowers eye pressure by draining pent-up aqueous humor in the eyethrough a network of microchannels. The device leverages a patented, ultrathin, nonfibrotic material with the goal of achieving greater patient comfort and aesthetics while minimizing foreign body response and reducing the risk of scarring, the leading cause of failure for existing glaucoma treatments. The VisiPlate procedure is designed to be easily performed by a surgeon in an outpatient setting and intended to not only control intraocular pressure, but also to improve patients’ quality of life.

About Glaucoma
Glaucoma is the leading cause of irreversible blindness in the world and currently has no cure. Glaucoma is a group of eye conditions that damage the optic nerve and is often related to high eye pressure. While damage to the optic nerve can cause vision loss, early treatment can usually stop disease progression and protect your vision.

About Avisi Technologies
Avisi is a medical device company dedicated to restoring health and promoting vitality in patients, starting with those facing vision loss. The company is developing a portfolio of ophthalmic treatments based on a novel metamaterial technology. To date, Avisi has been supported by venture investors as well as grants and awards from: the National Science Foundation, the University of Pennsylvania, the Singh Center for Nanotechnology, and others. Avisi is a proud member/alum of Johnson & Johnson JLABS incubator, UCSF Rosenman Innovators, and MedTech Innovator Accelerator.

Media & Investor Contact

Share this article:
Skip to content